PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
28.57 ^USD	+12.08%		+12.84%	+3.66%

Apr. 26	Sector Update: Health Care Stocks Edge Higher Late Afternoon	MT
Apr. 26	Sector Update: Health Care	MT

PTC Therapeutics' muscle disorder drug fails to secure EU regulator backing

January 25, 2024 at 04:20 pm EST

Jan 25 (Reuters) - The European health regulator's advisory panel issued a negative opinion for PTC Therapeutics' drug to treat Duchenne muscular dystrophy (DMD), an inherited progressive muscle-wasting disorder, the company said on Thursday. (Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)

Latest news about PTC Therapeutics, Inc.

Sector Update: Health Care Stocks Edge Higher Late Afternoon	Apr. 26	MT
Sector Update: Health Care	Apr. 26	MT
PTC Therapeutics Shares Rise After Better-Than-Expected Q1 Results	Apr. 26	MT
Earnings Flash (PTCT) PTC THERAPEUTICS Posts Q1 Revenue $210.1M, vs. Street Est of $163.8M	Apr. 25	MT
PTC Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Transcript : PTC Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Apr. 25	CI
PTC Therapeutics Seeks EMA Marketing Authorization for Sepiapterin for Phenylketonuria Treatment	Mar. 28	MT
PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	Mar. 28	CI
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza? as a Treatment for AADC Deficiency	Mar. 19	CI
Transcript : PTC Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 04:05 PM	Mar. 12
Transcript : PTC Therapeutics, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 01:30 PM	Mar. 04
PTC Therapeutics Shares Jump Following Q4 Results	Mar. 01	MT
TD Cowen Cuts Price Target on PTC Therapeutics to $30 From $32, Maintains Market Perform Rating	Mar. 01	MT
RBC Raises Price Target on PTC Therapeutics to $28 From $22, Keeps Sector Perform Rating	Mar. 01	MT
PTC Therapeutics Q4 Loss Narrows, Sales Up; Sets Guidance; Shares Slump After-Hours	Feb. 29	MT
PTC Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Transcript : PTC Therapeutics, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 29	CI
Earnings Flash (PTCT) PTC THERAPEUTICS Posts Q4 Revenue $307.1M, vs. Street Est of $317.9M	Feb. 29	MT
PTC Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Sector Update: Health Care Stocks Higher Friday Afternoon	Jan. 26	MT
Cantor Fitzgerald Cuts PTC Therapeutics' Price Target to $45 From $51, Keeps Overweight Rating	Jan. 26	MT
Global markets live: LVMH, Intel, Tesla, Salesforce, Eli Lilly...	Jan. 26
Inflation is just the icing on the cake	Jan. 26

Chart PTC Therapeutics, Inc.

Duration

Period

More charts

Company Profile

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - RBC Capital Markets Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for PTC Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

28.57 USD

Average target price

29.42 USD

Spread / Average Target

+2.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PTC THERAPEUTICS, INC.	+3.66%	2.19B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs